Cargando…

Cord Blood Transplantation: Can We Make it Better?

Umbilical cord blood is an established source of hematopoietic stem cells for transplantation. It enjoys several advantages over bone marrow or peripheral blood, including increased tolerance for Human Leukocyte Antigen mismatches, decreased incidence of graft-versus-host disease, and easy availabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metheny, Leland, Caimi, Paolo, de Lima, Marcos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774998/ https://www.ncbi.nlm.nih.gov/pubmed/24062989 http://dx.doi.org/10.3389/fonc.2013.00238

Ejemplares similares

Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens
por: Wang, Jiasheng, et al.
Publicado: (2023)

Umbilical cord blood derived cellular therapy: advances in clinical development
por: Wang, Jiasheng, et al.
Publicado: (2023)

Intra-osseous Co-transplantation of CD34-selected Umbilical Cord Blood and Mesenchymal Stromal Cells
por: Metheny, Leland, et al.
Publicado: (2016)

Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria
por: Ahmed, Nausheen, et al.
Publicado: (2021)

Can We Make Spine Surgery Safer and Better?
por: De la Garza Ramos, Rafael
Publicado: (2022)

Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?
por: Caimi, Paolo F., et al.
Publicado: (2014)

Can we make better use of our operating theatres?
por: Peruzzi, V, et al.
Publicado: (2023)

Acute kidney injury and chronic kidney disease in umbilical cord blood transplant recipients
por: Lopedote, Paolo, et al.
Publicado: (2023)

Impact of T Cell Repertoire Diversity on Mortality Following Cord Blood Transplantation
por: Milano, F., et al.
Publicado: (2020)

Socioeconomic Factors and Survival of Multiple Myeloma Patients
por: Chamoun, Kamal, et al.
Publicado: (2021)

Empowering patients in decision‐making in radiation oncology – can we do better?
por: Leech, Michelle, et al.
Publicado: (2020)

Clinical Impact of Delayed Initiation of Adjuvant Chemotherapy Among Patients With Stage II/III Gastric Cancer: Can We Do Better?
por: Chen, Qi-Yue, et al.
Publicado: (2020)

Gallbladder Cancer: We Need to Do Better!
por: Shukla, Parul J., et al.
Publicado: (2009)

Are We Making Personalized Cancer Care Less Personalized?
por: Sorscher, Steven
Publicado: (2016)

Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients
por: Troullioud Lucas, Alexandre G., et al.
Publicado: (2023)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients
por: Cheng, Tingting, et al.
Publicado: (2022)

Osteoarthritis: Can We Do Better?
por: Collins, Dylon P, et al.
Publicado: (2022)

Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate—Can We Make Better Use of It?
por: Guljaš, Silva, et al.
Publicado: (2022)

We can make it happen
por: Kallestrup, Per
Publicado: (2017)

Editorial: Have We Got Better in Making Our Schizophrenia Patients Better?
por: Jääskeläinen, Erika, et al.
Publicado: (2020)

Anesthesia-related mortality in children: the better we know the patient, the better we can predict it
por: Filho, Eduardo Mekitarian
Publicado: (2012)

Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
por: Ueda, Masumi, et al.
Publicado: (2020)

DIPG in Children – What Can We Learn from the Past?
por: Vanan, Magimairajan Issai, et al.
Publicado: (2015)

Influenza: Can we cope better with the unpredictable?
por: Dos Santos, Gaël, et al.
Publicado: (2015)

Pharmacy Internships: We Can Do Better
por: Nisly, Sarah, et al.
Publicado: (2018)

Innovation in Gastroenterology—Can We Do Better?
por: Klang, Eyal, et al.
Publicado: (2022)

Pediatric Kidney Transplantation—Can We Do Better? The Promise and Limitations of Epitope/Eplet Matching
por: Charnaya, Olga, et al.
Publicado: (2022)

Malaria: How Are We Doing and How Can We Do Better?
por: Rosenthal, Philip J., et al.
Publicado: (2019)

We can do much better than what we did
por: Lee, Sang-Hak
Publicado: (2020)

Can we make an anti-world
Publicado: (2009)

Can we make an anti-world?
Publicado: (2009)

Data reporting standards: making the things we use better
por: Quackenbush, John
Publicado: (2009)

Making Better Use of the Policies and Funding We Already Have
por: Baxter, Raymond J
Publicado: (2010)

What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?
por: Leite, Ana Carolina Rathsam, et al.
Publicado: (2022)

Polyorchidism and testicular malignancy, what can we learn: A case report
por: Nurfajri, Derri Hafa, et al.
Publicado: (2021)

How can we better predict pulmonary blood clots in patients hospitalised for COVID-19?
por: Bertoletti, Laurent, et al.
Publicado: (2020)

A six-microRNA signature can better predict overall survival of patients with esophagus adenocarcinoma
por: Lan, Tian, et al.
Publicado: (2019)

Myocardial infarction on the ICU: can we do better?
por: Webb, Ian, et al.
Publicado: (2008)

Can we manage B3 lesions better?
por: Pinder, S
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1lqba8ohucu0fed8mn1e6ihhek